Race in a bottle : the story of BiDil and racialized medicine in a post-genomic age /

Mostrar otras versiones (1)

Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was touted as a pathbreaking therapy to treat heart failure in black patients. Kahn reveals that, at the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much a...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Kahn, Jonathan (Autor)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Columbia University Press, 2012.
Temas:
Hydralazine > Development > History.
Health and race.
African Americans > Medical care.
Pharmacogenetics > Social aspects.
Pharmaceutical industry > Political aspects > United States.
African Americans.
Pharmacogenetics.
Hydralazine > therapeutic use
Isosorbide Dinitrate > therapeutic use
Heart Failure > drug therapy
Heart Failure > ethnology
Black or African American
Pharmacogenetics
Santé et race.
Noirs américains > Soins médicaux.
Pharmacogénétique > Aspect social.
Industrie pharmaceutique > Aspect politique > États-Unis.
Noirs américains.
Pharmacogénétique.
African American.
HEALTH & FITNESS > Diseases > Heart.
MEDICAL > Cardiology.
MEDICAL > Ethics.
African Americans
African Americans > Medical care
Health and race
United States
Electronic books.
History
Acceso en línea:Texto completo

Internet

Texto completo

Items no disponibles

Detalle de Existencias desde

Ejemplares similares